| Authors: |
Vrenken P; Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis, Zografou, Greece; Bayer AG, Pharmacometrics/Modeling and Simulation, Model-Informed Drug Development, Leverkusen, Germany., Vertzoni M; Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis, Zografou, Greece., Frechen S; Bayer AG, Pharmacometrics/Modeling and Simulation, Model-Informed Drug Development, Leverkusen, Germany., Solodenko J; Bayer AG, Pharmacometrics/Modeling and Simulation, Model-Informed Drug Development, Leverkusen, Germany., Meyer M; Bayer AG, Pharmacometrics/Modeling and Simulation, Model-Informed Drug Development, Leverkusen, Germany., Muenster U; Bayer AG, Research and Development, Pharmaceutical Sciences, Advanced Drug Delivery, Wuppertal, Germany., Dallmann A; Bayer HealthCare SAS, Lille, France, on Behalf of Bayer AG, Model-Informed Drug Development, 1 Rue Claude Bernard, Leverkusen, Lille 59000, Germany. Electronic address: andre.dallmann@bayer.com. |
